Characterisation of Alzheimer’s disease biomarker discrepancies


  • Heather Mason
  • Univadis Medical News
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

Some biomarkers of Alzheimer disease (AD) may reveal earlier stages of disease, a new study suggests.

Tau pathology in cerebrospinal fluid (CSF) and positron emission tomography (PET) was assessed from a cohort of 322 participants in the Alzheimer’s Disease Neuroimaging Initiative. Patients were either cognitively unimpaired (CU) (n=213), had mild cognitive impairment (MCI) (n=98), or had AD dementia (n=11).

Clinically relevant thresholds for CSF phosphorylated tau (P-tau) (≥26.64 pg/mL) and flortaucipir-PET meta-regions of interest (ROI) (standard uptake value ratio -1.37) indicated participants’ tau status as CSF-/PET- (n=210), CSF+/PET- (n=63), CSF-/PET+ (n=15), and CSF+/PET+ (n=34).

Comparisons were made between tau-positive and tau-negative groups, demographic and clinical variables, amyloid β-PET burden, and flortaucipir-PET binding across Braak stage-related ROIs. Rates of tau accumulation in CSF and cognitive decline were also compared.

One-third of participants had abnormal CSF tau or were tau positive on both CSF assay and PET.

Tau-positive individuals showed increased amyloid β-PET burden. Tau-positive individuals had a history of accelerated CSF tau accrual, but only persons with tau-PET abnormality showed a similar significant decline in cognition.

The authors concluded that elevation of CSF P-tau appears to precede flortaucipir-PET detection and may occur before measurable cognitive decline.